Navigation Links
Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine
Date:11/1/2010

will receive an injection of either a placebo or the H5N1 vaccine at varying doses to determine the optimal dose. In the second part of the study, healthy adults will receive an injection of either a placebo or the H5N1 vaccine at the optimal dose. Interim-results of this study are expected in less than three months.

"The initiation of our Phase II clinical trial is an important step in the development of our plant-based VLP vaccines, which we believe are highly effective, cross-protective, less expensive and faster to produce than current influenza vaccines. It also demonstrates our ability to advance candidates through clinical development," said Andy Sheldon, President and CEO of Medicago. "Our platform is very versatile and to date, we have been able to produce a broad array of other proteins with potential use in the life science industry. This clinical trial therefore provides additional validation for our rapid and cost-effective technology platform offering." About Medicago Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-loo
'/>"/>

SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. Medicago reports positive Phase I results for its avian flu pandemic vaccine
9. Medicago named in Presidential report on meeting the challenges of pandemic influenza
10. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
11. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2University of Illinois study advances limits for ultrafast nano-devices 2
... Issues Have Been Resolved; Remaining Issues Pertain to ... of Third-party Manufacturing Facility Company Expects to ... LEXINGTON, Mass., Dec. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... letter from the U.S. Food and Drug Administration (FDA) ...
... Allows Accurate Marketing Claims Designed with Input from,Entire ... nation,s leading livestock,cloning companies announced today a tracking ... allow food companies to identify cloned animals,when they ... program was developed through extensive cooperative discussions,over the ...
... Announcement of a Tracking Program for,Cloned Livestock, ... by International Dairy Foods Association President and CEO ... new national registry to track cloned,livestock as a ... food,products from cloned animals. However, we strongly urge ...
Cached Biology Technology:Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 2Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 3Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM) 4Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2Statement of International Dairy Foods Association President and CEO Connie Tipton 2
(Date:7/11/2014)... the normal circumstances, astrocytes participate in normal ... and exhibit therapeutic and repairing effects on ... have found that nerve cells differentiated from ... reduced viability, which produces influences on subsequent ... General Hospital, Hebei United University, China demonstrated ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... software and services, previously announced on June 26, 2014 ... cash dividend of $1.75 per share, or approximately $40 ... of July 10, 2014 and a payment date of ... NASDAQ that it had set an ex-dividend date for ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... a fetus to get nutrition and oxygen from its mother,s ... That crosstalk allows the mother,s blood to flow out of ... away from the fetus, blood, says Dr. Puttur D. Prasad, ... That controlled exchange between the blood of mother and ...
... Think researchers know all there is to know about ... "E. coli has more than four thousand genes, and ... Dr. Deborah Siegele, a biology professor at Texas A&M ... the bacterium. , Harmless E. coli strains are normally ...
... The Iowa Corn Promotion Board (ICPB), NJIT and University ... licensing four pending patents on a safe, building block ... The agreement marks a step forward in developing ... "This agreement gives us the exclusive right to work ...
Cached Biology News:Likely cause of postpartum blues and depression identified 2Likely cause of postpartum blues and depression identified 3GIANT-Coli: A novel method to quicken discovery of gene function 2Iowa Corn Promotion Board, NJIT to license breakthrough, safe bio-plastic alternative 2
... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
...
... Deletion Cosmid Cloning Kit enables you to ... and unbiased primary cosmid library of genomic ... deletion sublibraries. High efficiency cosmid library construction ... kit protocols. First, genomic DNA is randomly ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Biology Products: